

Special Issue

Advances in PET/CT Application in Urological Cancer

Message from the Guest Editor

PSMA-PET CT has been gaining increasing importance in the field of prostate cancer (PCa), as its superiority to conventional imaging in detecting PCa and its metastases have been demonstrated. PSMA-PET CT can be offered in different clinical settings, from the primary staging of prostatic cancer to the re-staging in cases of biochemical recurrence or in the management of metastatic diseases. For this reason, much of the guidelines emphasize the best performance of this diagnostic method, although its impact on clinical outcomes remains to be proven. On the other hand, theranostics is the new frontier of nuclear medicine; PSMA radioligand treatment is now approved in the metastatic stage of prostate cancer, while many ongoing trials are exploring its possible role in less-advanced stages. Furthermore, several radiotracers have been evaluated for the diagnosis, staging and management of other urological neoplasms, such as urothelial and kidney cancers. This Special Issue will cover the different areas of the application of PET CT imaging in the overall management of urological neoplasms.

Guest Editor

Dr. Marco Roscigno
Department of Urology, ASST Papa Giovanni XXIII, 24125 Bergamo, Italy

Deadline for manuscript submissions

closed (28 February 2026)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/215183

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)